Overactive Bladder - Results from #180

Real-World Compliance with Percutaneous Tibial Nerve Stimulation Maintenance Therapy in an American Population. February 14, 2021

Patient preference elicitation instrument, OABCare, to facilitate shared decision-making in the care of overactive bladder. February 14, 2021

Considering non-bladder etiologies of overactive bladder: A functional neuroimaging study. February 7, 2021

Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options. February 7, 2021

Consideration of pelvic floor myofascial release for overactive bladder. February 7, 2021

Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia. February 7, 2021

Long-term effectiveness of an intervention to enhance mirabegron use revision and its deprescribing: 36-month follow-up of a quasi-experimental trial in primary care. February 7, 2021

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study. January 31, 2021

Pharmacist's knowledge regarding the management of overactive bladder in elderly women. January 31, 2021

An exploratory analysis of tamsulosin for Overactive Bladder (OAB) in men with varying voiding symptom burden. January 24, 2021

Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting. January 24, 2021

Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial. January 17, 2021

Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): A Potential Alternative to the Standard Bladder Diary for Monitoring OAB Outcomes. January 17, 2021

Potential Role of Monocyte Chemoattractant Protein-1 in Monitoring Disease Progression and Response to Treatment in Overactive Bladder Patients. January 10, 2021

Clinical Manifestations of Overactive Bladder With Migraine as a Comorbidity: A Prospective Cross-Sectional Study. January 10, 2021

Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. January 10, 2021

Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy. January 10, 2021

GEMTESA® (vibegron) Receives U.S. FDA Approval for the Treatment of Patients with Overactive Bladder (OAB) January 4, 2021

Adverse Childhood Experiences in Women With Overactive Bladder or Interstitial Cystitis/Bladder Pain Syndrome. January 3, 2021

Detrusor Overactivity May Be a Prognostic Factor for Better Response to Combination Therapy Over Monotherapy in Male Patients With Benign Prostatic Enlargement and Storage Lower Urinary Tract Symptoms. January 3, 2021

Page 10 of 102

email news signup